Identifying responders and nonresponders to interferon therapy in multiple sclerosis

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343:938–952.11006371
   PubMed Web of Science ®Google Scholar
• Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol. 2004;55:65–71.14705113
   PubMed Web of Science ®Google Scholar
• Noseworthy JH. Therapeutics of multiple sclerosis. Clin Neuropharmacol. 1991;14:49–61.2029693
   PubMed Web of Science ®Google Scholar
• Freedman MS. ‘Time is brain’ also in multiple sclerosis. Mult Scler. 2009;15:1133–1134.19808740
   PubMed Web of Science ®Google Scholar
• The IFN Beta Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43: 655–661.8469318
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285–294.8602746
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352:1498–1504.9820297
   PubMed Web of Science ®Google Scholar
• Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFN Beta Multiple Sclerosis Study Group. Neurology. 1993;43:662–667.8469319
   PubMed Web of Science ®Google Scholar
• Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative research Group. Ann Neurol. 1998;43: 79–87.9450771
   PubMed Web of Science ®Google Scholar
• Li DK, Paty DW. Magnetic Resonance Imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis. Ann Neurol. 1999;42:197–206.
   Web of Science ®Google Scholar
• Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler. 2010;16:588–596.20167591
   PubMed Web of Science ®Google Scholar
• Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord. 2011;4:3–14.21339904
   PubMedGoogle Scholar
• Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A. The effects of long-term interferon- beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler. 2013;19:1765–1772.23652214
   PubMed Web of Science ®Google Scholar
• Paolillo A, Pozzilli C, Giugni E, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Eur J Neurol. 2002;9:645–655.12453081
   PubMed Web of Science ®Google Scholar
• Río J, Tintoré M, Nos C, et al. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol. 2005;252:795–800.15772741
   PubMed Web of Science ®Google Scholar
• Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol. 2007;61: 300–306.17444502
   PubMed Web of Science ®Google Scholar
• Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNB-1b trial. Neurology. 2012;78:1315–1322.22496198
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343:898–904.11006365
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576–1582.11377645
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndrome. Neurology. 2006;67: 1242–1249.16914693
   PubMed Web of Science ®Google Scholar
• Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11:33–41.22146409
   PubMed Web of Science ®Google Scholar
• Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009;8:545–559.19446274
   PubMed Web of Science ®Google Scholar
• Naismith RT. Multiple sclerosis therapeutic strategies: start safe and effective, reassess early, and escalate if necessary. Neurol Clin Pract. 2011;1:69–71.23634357
   PubMedGoogle Scholar
• Sormani MP, De Stefano N. Defining and scoring response to IFNB in multiple sclerosis. Nat Rev Neurol. 2013;9:504–512.23897407
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Prosperini L. Clinical markers of therapeutic response to disease modifying drugs. Neurol Sci. 2008;29 Suppl 2:S211–S213.18690494
   PubMed Web of Science ®Google Scholar
• Rio J, Nos C, Tintoré M, et al. Defining the response to interferon beta in relapsing-remitting multiple sclerosis patients. Ann Neurol. 2006;59: 344–352.16437558
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurological impairment in Multiple Sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.6685237
   PubMed Web of Science ®Google Scholar
• Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871–882.10355672
   PubMed Web of Science ®Google Scholar
• Río J, Nos C, Tintoré M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol. 2002;52:400–406.12325067
   PubMed Web of Science ®Google Scholar
• Roullet E, Dominique P, Le Canuet P, et al. Application of different criteria for clinical response to beta-interferon in relapsing-remitting multiple sclerosis. Neurology. 2003;60 Suppl 1:A168.
   Google Scholar
• Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. 2003;61: 184–189.12874396
   PubMed Web of Science ®Google Scholar
• Trojano M, Liguori M, Paolicelli D, et al. Southern Italy MS Group. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler. 2003;9:451–457.14582768
   PubMed Web of Science ®Google Scholar
• Coppola G, Lanzillo R, Florio C, et al. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. Eur J Neurol. 2006;13:1014–1021.16930370
   PubMed Web of Science ®Google Scholar
• Portaccio E, Zipoli V, Siracusa G, et al. Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult Scler. 2006;12:281–286.16764340
   PubMed Web of Science ®Google Scholar
• O’Rourke K, Walsh C, Antonelli G, et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler. 2007;13: 336–342.17439902
   PubMed Web of Science ®Google Scholar
• Fromont A, Debouverie M, Le Teuff G, et al. Clinical parameters to predict response to interferon in relapsing multiple sclerosis. Neuroepidemiology. 2008;31:150–156.18716412
   PubMed Web of Science ®Google Scholar
• Goodin D, Traboulsee A, Knappertz V, et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83:282–287.22193561
   PubMed Web of Science ®Google Scholar
• Mezei Z, Bereczki D, Racz L, et al. Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis? Neuropsychiatr Dis Treat. 2012;8: 465–473.23118540
   PubMed Web of Science ®Google Scholar
• Miller DH, Grossman R, Reingold S, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 1998;121:3–24.9549485
   PubMed Web of Science ®Google Scholar
• Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998;51:682–689.9748010
   PubMed Web of Science ®Google Scholar
• Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol. 2004;56:548–555.15389896
   PubMed Web of Science ®Google Scholar
• Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol. 2006;253:287–293.16151600
   PubMed Web of Science ®Google Scholar
• Durelli L, Berbero P, Bergui M, et al. MRI activity and neutralizing antibody as predictor of response to IFNB treatment in MS. J Neurol Neurosurg Psychiatry. 2008;79:646–651.17986500
   PubMed Web of Science ®Google Scholar
• Rio J, Rovira A, Tintoré M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler. 2008;14:479–484.18562504
   PubMed Web of Science ®Google Scholar
• Prosperini L, Gallo V, Petsas N, et al. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol. 2009;16:1202–1209.19538207
   PubMed Web of Science ®Google Scholar
• Freedman M, Hartung HP, Miller D, et al. Predictors of disease activity in CIS patients treated with IFNB-1b in the BENEFIT study. Mult Scler. 2011;17 Suppl 10:S16/O31.
   Google Scholar
• Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol. 2013;73:95–103.23378325
   PubMed Web of Science ®Google Scholar
• Horakova D, Kalincik T, Dolezal O, et al. Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand. 2012;126:390–397.22428845
   PubMed Web of Science ®Google Scholar
• Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009;65:268–275.19334061
   PubMed Web of Science ®Google Scholar
• Sormani MP, Stubinski B, Cornelisse P, et al. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler. 2011;17:541–549.21148262
   PubMed Web of Science ®Google Scholar
• Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12:669–676.23743084
   PubMed Web of Science ®Google Scholar
• Prosperini L, Mancinelli CR, De Giglio L, et al. Interferon-beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Mult Scler. September 3, 2013 [ Epub ahead of print.]
   Google Scholar
• Rio J, Castilló J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler. 2009;15: 848–853.19542263
   PubMed Web of Science ®Google Scholar
• Sormani M, Rio J, Tintorè M, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013;19:605–612.23012253
   PubMed Web of Science ®Google Scholar
• Sormani M, Signori A, Stromillo M, De Stefano N. Refining response to treatment as defined by the Modified Rio Score. Mult Scler. 2013;19: 1246–1247.23549435
   PubMed Web of Science ®Google Scholar
• Sormani MP, Li DK, Bruzzi P, et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology. 2011;77:1684–1690.21975200
   PubMed Web of Science ®Google Scholar
• Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS Working Group Updated Recommendations. Can J Neurol Sci. 2013;40:307–323.23603165
   PubMed Web of Science ®Google Scholar
• Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.11240971
   PubMed Web of Science ®Google Scholar
• Creeke PI, Farrell RA. Clinical testing for neutralizing antibodies to interferon-beta in multiple sclerosis. Ther Adv Neurol Disord. 2013;6:3–17.23277789
   PubMed Web of Science ®Google Scholar
• Malucchi S, Gilli F, Caldano M, et al. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol. 2011;258:895–903.21153733
   PubMed Web of Science ®Google Scholar
• Deisenhammer F, Reindel M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology. 1999;52:1239–1243.10214750
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology. 2005;65:33–39.15888603
   PubMed Web of Science ®Google Scholar
• Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralizing antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010;9:740–750.20610349
   PubMed Web of Science ®Google Scholar
• Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutalizing antibodies to interferon beta 1a in multiple sclerosis. Neurology. 1998;50:1266–1272.9595973
   PubMed Web of Science ®Google Scholar
• Li DK, Zhao MD, Paty DW; University of British Columbia MS/MRI Analysis Group. The SPRECTRIMS Study Group. Randomized controlled trial of interferon-beta 1a in secondary progressive MS. MRI results. Neurology. 2001;56:1505–1513.11402107
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al; for the EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferonβ-1a treatment regimens in MS. The EVIDENCE Trial. Neurology. 2002;59:1496–1506.12451188
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P, et al; and the Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453–1460.11988242
   PubMed Web of Science ®Google Scholar
• Polman C, Kappos L, White R, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology. 2003;60:37–43.12525715
   PubMed Web of Science ®Google Scholar
• Panitch H, Miller A, Paty D, Weinshenker B; The North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS. Results from a 3-year controlled study. Neurology. 2004;3:1788–1795.
   Google Scholar
• Francis GS, Rice GP, Alsop JC, et al. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology. 2005;65:48–55.16009884
   PubMed Web of Science ®Google Scholar
• Kappos L, Clanet M, Sandberg W, et al. Neutralizing antibodies and efficacy of interferon β-1a: a 4 year controlled study. Neurology. 2005;65:40–47.16009883
   PubMed Web of Science ®Google Scholar
• Hartung HP, Freedman MF, Polman CH, et al; for the BENEFIT Study Group. Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology. 2011;77:835–843.21849647
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Ross C, Clemmensen KM, et al; The Danish Multiple Sclerosis Study Group. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362:1184–1191.14568740
   PubMed Web of Science ®Google Scholar
• Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of beta IFNB during treatment of multiple sclerosis. Neurology. 2004;62:2031–2037.15184610
   PubMed Web of Science ®Google Scholar
• Frank JA, Richert N, Bash C, et al. Interferon beta-1b slows progression of atrophy in RRMS. Three-year follow-up in Nab+ and Nab- patients. Neurology. 2004;62:719–725.15007120
   PubMed Web of Science ®Google Scholar
• Perini P, Calabrese M, Biasi G, Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol. 2004;251: 305–309.15015010
   PubMed Web of Science ®Google Scholar
• Boz C, Oger J, Gibbs E, et al. Reduced effectiveness of long-term interferon-treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler. 2007;13:1127–1137.17967840
   PubMed Web of Science ®Google Scholar
• Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology. 2008;70:119–127.
   Web of Science ®Google Scholar
• Sato DK, Nakashima I, Fukazawa T, et al. Neutralizing antibodies are associated with a reduction of interferon-b efficacy during the treatment of Japanese multiple sclerosis patients. Tohoku J Exp Med. 2012;228: 85–92.22976494
   PubMed Web of Science ®Google Scholar
• Paolicelli D, D’Onghia M, Pellegrini F, et al. The impact of neutralizing antibodies on the risk of disease worsening in interferon b-treated relapsing multiple sclerosis: a 5 year post-marketing study. J Neurol. 2013;260:1562–1568.23417273
   PubMed Web of Science ®Google Scholar
• Gilli F, Valentino P, Caldano M, et al. Expression and regulation of IFN alpha/beta receptor in IFNB-treated patients with multiple sclerosis. Neurology. 2008;71:1940–1947.18971450
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Gilli F, Sala A, et al. Evaluation of bioavailability of three types of IFN beta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods. 2001;256:141–152.11516761
   PubMed Web of Science ®Google Scholar
• Pachner A, Narayan K, Price N, et al. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn. 2003;7:17–25.14529316
   PubMedGoogle Scholar
• Wandinger KP, Lünemann JD, Wengert O, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet. 2003;361:2036–2043.12814715
   PubMed Web of Science ®Google Scholar
• Gilli F, Marnetto F, Caldano M, et al. Biological markers of IFN beta therapy: comparison among interferon-stimulated-genes MxA, TRAIL, and XAF-1. Mult Scler. 2006;12:1–11.
   Web of Science ®Google Scholar
• Pachner AR, Warth JD, Pace A, et al. Effect of neutralizing antibodies on biomarker responses to interferon beta. The INSIGHT study. Neurology. 2009;73:1493–1500.19884577
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Krakauer M, Hesse D, et al. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol. 2009;16: 1291–1298.19558503
   PubMed Web of Science ®Google Scholar
• Hesse D, Sellbjerg F, Sorensen PS. Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity. Neurology. 2009;73:372–377.19652141
   PubMed Web of Science ®Google Scholar
• Zanotti C, Ghidini C, Lamorgese C, Caimi L, Capra R, Imberti L. Transfer of myxovirus-protein-A mRNA assay for interferon-beta bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience. Clin Chem Lab Med. 2010;48:1235–1238.20678029
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology. 2003;60:634–639.12601105
   PubMed Web of Science ®Google Scholar
• Van der Voort LF, Vennegoor A, Visser A, et al. Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology. 2010;75:1228–1233.20921509
   PubMed Web of Science ®Google Scholar
• Malhotra S, Bustamante MF, Pérez-Miralles F, et al. Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis. PLoS One. 2011;6:e23634.21886806
   PubMed Web of Science ®Google Scholar
• Malhotra S, Morcillo-Suarez C, Nurtdinova S, et al. Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-b treatment. Eur J Neurol. 2013;20:1390–1397.23700969
   PubMed Web of Science ®Google Scholar
• Paap BK, Hundeshagen A, Hecker M, Zettl UK. An inventory of short term and long term changes in gene expression under interferon treatment of relapsing remitting MS patients. Curr Pharm Design. 2012;18:4475–4484.
   Web of Science ®Google Scholar
• Croze E, Yamaguchi KD, Knappertz V, et al. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J. 2013;13:443–451.22711062
   PubMed Web of Science ®Google Scholar
• Comabella M, Lunemann JD, Rio J, et al. A type 1 interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009;132:3353–3365.19741051
   PubMed Web of Science ®Google Scholar